Response to fumaric acid esters for plaque type psoriasis in real-world practice is largely independent of patient characteristics at baseline – a multivariable regression analysis from the German Psoriasis Registry PsoBest

References

• Parisi R, Symmons DPM, Griffiths CEM, et al. Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) Project Team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–385.
   PubMed Web of Science ®Google Scholar
• Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496–509.
   PubMed Web of Science ®Google Scholar
• Blome C, Gosau R, Radtke MA, et al. Patient-relevant treatment goals in psoriasis. Arch Dermatol Res. 2016;308(2):69–78.
   PubMed Web of Science ®Google Scholar
• Nast A, Amelunxen L, Augustin M, et al. S3 guideline for the treatment of psoriasis vulgaris, update – short version part 1 – systemic treatment. J Dtsch Dermatol Ges. 2018;16(5):645–669.
   Web of Science ®Google Scholar
• Augustin M. Einsatz von Systemtherapeutika und Biologika in der leitliniengerechten Therapie der mittelschweren bis schweren Psoriasis vulgaris. PsoNet Magazin. 2017;4(Suppl):1–28.
   Google Scholar
• Mrowietz U, Morrison PJ, Suhrkamp I, et al. The pharmacokinetics of fumaric acid esters reveal their in vivo effects. Trends Pharmacol Sci. 2018;39(1):1–12.
   PubMed Web of Science ®Google Scholar
• Brück J, Dringen R, Amasuno A, et al. A review of the mechanisms of action of dimethylfumarate in the treatment of psoriasis. Exp Dermatol. 2018;27(6):611–624.
   PubMed Web of Science ®Google Scholar
• Hanson J, Gille A, Offermanns S. Role of HCA2 (GPR109A) in nicotinic acid and fumaric acid ester-induced effects on the skin. Pharmacol Ther. 2012;136(1):1–7.
   PubMed Web of Science ®Google Scholar
• Müller S, Behnen M, Bieber K, et al. Dimethylfumarate impairs neutrophil functions. J Invest Dermatol. 2016;136(1):117–126.
   PubMed Web of Science ®Google Scholar
• Tang H, Lu JY-L, Zheng X, et al. The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist. Biochem Biophys Res Commun. 2008;375(4):562–565.
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Brück J, Kellerer C, et al. Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med. 2011;208(11):2291–2303.
   PubMed Web of Science ®Google Scholar
• Brennan MS, Matos MF, Li B, et al. Dimethyl fumarate and monoethyl fumarate exhibit differential effects on KEAP1, NRF2 activation, and glutathione depletion in vitro. PLoS One 2015;10(3):e0120254.
   PubMed Web of Science ®Google Scholar
• Ruggieri S, Tortorella C, Gasperini C. Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing-remitting multiple sclerosis. Ther Clin Risk Manag. 2014;10:229–239.
   PubMed Web of Science ®Google Scholar
• Nast A, Boehncke W-H, Mrowietz U, et al. S3-Leitlinie zur Therapie der Psoriasis vulgaris Update 2011. J Dtsch Dermatol Ges. 2011;9(Suppl 2):S1–S104.
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Szepietowski JC, Loewe R, et al. Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm® – and placebo-controlled trial (BRIDGE). Br J Dermatol. 2017;176(3):615–623.
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Barker J, Boehncke W-H, et al. Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis: a European expert consensus. J Eur Acad Dermatol Venereol. 2018;32(Suppl 3):3–14.
   PubMedGoogle Scholar
• Reich K, Thaci D, Mrowietz U, et al. Efficacy and safety of fumaric acid esters in the long-term treatment of psoriasis–a retrospective study (FUTURE). J Dtsch Dermatol Ges. 2009;7(7):603–611.
   PubMed Web of Science ®Google Scholar
• Thaçi D, Weisenseel P, Philipp S, et al. Efficacy and safety of fumaric acid esters in patients with psoriasis on medication for comorbid conditions – a retrospective evaluation (FACTS). J Dtsch Dermatol Ges. 2013;11(5):429–435.
   PubMed Web of Science ®Google Scholar
• Dickel H, Bruckner T, Altmeyer P. Long-term real-life safety profile and effectiveness of fumaric acid esters in psoriasis patients: a single-centre, retrospective, observational study. J Eur Acad Dermatol Venereol. 2018;32(10):1710–1727.
   PubMed Web of Science ®Google Scholar
• Naldi L, Addis A, Chimenti S, et al. Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the psocare project. Dermatology 2008;217(4):365–373.
   PubMed Web of Science ®Google Scholar
• Montaudié H, Sbidian E, Paul C, et al. Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity. J Eur Acad Dermatol Venereol. 2011;25(Suppl 2):12–18.
   PubMed Web of Science ®Google Scholar
• Edson-Heredia E, Sterling KL, Alatorre CI, et al. Heterogeneity of response to biologic treatment: perspective for psoriasis. J Invest Dermatol. 2014;134(1):18–23.
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Sorbe C, Reich K, et al. Fumaric acid esters for the treatment of psoriasis in Germany: characterising patients in routine care. Eur J Dermatol. 2020;30(1):41–48.
   PubMed Web of Science ®Google Scholar
• Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–216.
   PubMed Web of Science ®Google Scholar
• Augustin M, Spehr C, Radtke MA, et al. German psoriasis registry PsoBest: objectives, methodology and baseline data. J Dtsch Dermatol Ges. 2014;12(1):48–57.
   PubMed Web of Science ®Google Scholar
• Kelley K, Preacher KJ. On effect size. Psychol Methods. 2012;17(2):137–152.
   PubMed Web of Science ®Google Scholar
• Sticherling M, Mrowietz U, Augustin M, et al. Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial. Br J Dermatol. 2017;177(4):1024–1032.
   PubMed Web of Science ®Google Scholar
• Cassano N, Galluccio A, Simone C D, et al. Influence of body mass index, comorbidities and prior systemic therapies on the response of psoriasis to adalimumab: an exploratory analysis from the APHRODITE data. J Biol Regul Homeost Agents. 2008;22(4):233–237.
   PubMed Web of Science ®Google Scholar
• Driessen RJB, Boezeman JB, van de Kerkhof PCM, et al. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome. Br J Dermatol. 2009;160(3):670–675.
   PubMed Web of Science ®Google Scholar
• Brewer L, Rogers S. Fumaric acid esters in the management of severe psoriasis. Clin Exp Dermatol. 2007;32(3):246–249.
   PubMed Web of Science ®Google Scholar
• Boehncke S, Fichtlscherer S, Salgo R, et al. Systemic therapy of plaque-type psoriasis ameliorates endothelial cell function: results of a prospective longitudinal pilot trial. Arch Dermatol Res. 2011;303(6):381–388.
   PubMed Web of Science ®Google Scholar
• Salmen A, Gold R. Mode of action and clinical studies with fumarates in multiple sclerosis. Exp Neurol. 2014;262(Pt A):52–56.
   PubMedGoogle Scholar
• Cuadrado A, Manda G, Hassan A, et al. Transcription factor NRF2 as a therapeutic target for chronic diseases: a systems medicine approach. Pharmacol Rev. 2018;70(2):348–383.
   PubMed Web of Science ®Google Scholar
• Zhou S, Jin J, Bai T, et al. Potential drugs which activate nuclear factor E2-related factor 2 signaling to prevent diabetic cardiovascular complications: a focus on fumaric acid esters. Life Sci. 2015;134:56–62.
   PubMed Web of Science ®Google Scholar
• Amin FM, Abdelaziz RR, Hamed MF, et al. Dimethyl fumarate ameliorates diabetes-associated vascular complications through ROS-TXNIP-NLRP3 inflammasome pathway. Life Sci. 2020;256:117887.
   PubMed Web of Science ®Google Scholar
• Gerhardt S, König V, Doll M, et al. Dimethylfumarate protects against TNF-α-induced secretion of inflammatory cytokines in human endothelial cells. J Inflamm. 2015;12:49.
   Google Scholar
• Lin-Holderer J, Li L, Gruneberg D, et al. Fumaric acid esters promote neuronal survival upon ischemic stress through activation of the Nrf2 but not HIF-1 signaling pathway. Neuropharmacology 2016;105:228–240.
   PubMed Web of Science ®Google Scholar
• Luo M, Sun Q, Zhao H, et al. The effects of dimethyl fumarate on atherosclerosis in the apolipoprotein E-deficient mouse model with streptozotocin-induced hyperglycemia mediated by the nuclear factor erythroid 2-Related factor 2/antioxidant response element (Nrf2/ARE) signaling pathway. Med Sci Monit. 2019;25:7966–7975.
   PubMed Web of Science ®Google Scholar
• Ashrafian H, Czibik G, Bellahcene M, et al. Fumarate is cardioprotective via activation of the Nrf2 antioxidant pathway. Cell Metab. 2012;15(3):361–371.
   PubMed Web of Science ®Google Scholar
• Ibrahim SG, El-Emam SZ, Mohamed EA, et al. Dimethyl fumarate and curcumin attenuate hepatic ischemia/reperfusion injury via Nrf2/HO-1 activation and anti-inflammatory properties. Int Immunopharmacol. 2020;80:106131.
   PubMed Web of Science ®Google Scholar
• Ganzetti G, Campanati A, Molinelli E, et al. Psoriasis, non-alcoholic fatty liver disease, and cardiovascular disease: Three different diseases on a unique background. World J Cardiol. 2016;8(2):120–131.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Del Giglio M, Girolomoni G. Considerations for systemic treatment of psoriasis in obese patients. Am J Clin Dermatol. 2016;17(6):609–615.
   PubMed Web of Science ®Google Scholar